CN1552309A - 一种促进西洛他唑固体制剂药物溶出的方法 - Google Patents
一种促进西洛他唑固体制剂药物溶出的方法 Download PDFInfo
- Publication number
- CN1552309A CN1552309A CNA031408966A CN03140896A CN1552309A CN 1552309 A CN1552309 A CN 1552309A CN A031408966 A CNA031408966 A CN A031408966A CN 03140896 A CN03140896 A CN 03140896A CN 1552309 A CN1552309 A CN 1552309A
- Authority
- CN
- China
- Prior art keywords
- cilostazol
- preparation
- weight
- stripping
- hydroaropic substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 title claims abstract description 34
- 229960004588 cilostazol Drugs 0.000 title claims abstract description 34
- 239000007787 solid Substances 0.000 title claims description 15
- 238000000034 method Methods 0.000 title abstract description 8
- 230000001737 promoting effect Effects 0.000 title 1
- 239000000126 substance Substances 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 16
- 239000008187 granular material Substances 0.000 claims description 14
- 229920002472 Starch Polymers 0.000 claims description 7
- 230000001476 alcoholic effect Effects 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 241001597008 Nomeidae Species 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 239000006184 cosolvent Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- -1 polyethylene ketopyrrolidine Polymers 0.000 claims 1
- 229940126589 solid medicine Drugs 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 9
- 239000008108 microcrystalline cellulose Substances 0.000 description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 239000000243 solution Substances 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 229920000881 Modified starch Polymers 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 206010022562 Intermittent claudication Diseases 0.000 description 4
- 238000007605 air drying Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 208000021156 intermittent vascular claudication Diseases 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 150000003248 quinolines Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 208000033386 Buerger disease Diseases 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 230000006502 antiplatelets effects Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031408966A CN100518737C (zh) | 2003-06-06 | 2003-06-06 | 一种西洛他唑固体制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031408966A CN100518737C (zh) | 2003-06-06 | 2003-06-06 | 一种西洛他唑固体制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1552309A true CN1552309A (zh) | 2004-12-08 |
CN100518737C CN100518737C (zh) | 2009-07-29 |
Family
ID=34323926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031408966A Expired - Lifetime CN100518737C (zh) | 2003-06-06 | 2003-06-06 | 一种西洛他唑固体制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100518737C (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106214637A (zh) * | 2016-07-28 | 2016-12-14 | 北京万全德众医药生物技术有限公司 | 一种阿立哌唑共研磨物及分散片制备技术 |
CN114533690A (zh) * | 2022-03-22 | 2022-05-27 | 许昌市中心医院 | 含抗凝血药物西洛他唑的新制剂及其制备方法 |
WO2022228324A1 (zh) * | 2021-04-30 | 2022-11-03 | 北京华亘安邦科技有限公司 | 13c美沙西汀颗粒剂及其制备方法和应用 |
-
2003
- 2003-06-06 CN CNB031408966A patent/CN100518737C/zh not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106214637A (zh) * | 2016-07-28 | 2016-12-14 | 北京万全德众医药生物技术有限公司 | 一种阿立哌唑共研磨物及分散片制备技术 |
WO2022228324A1 (zh) * | 2021-04-30 | 2022-11-03 | 北京华亘安邦科技有限公司 | 13c美沙西汀颗粒剂及其制备方法和应用 |
CN114533690A (zh) * | 2022-03-22 | 2022-05-27 | 许昌市中心医院 | 含抗凝血药物西洛他唑的新制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100518737C (zh) | 2009-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2205000T5 (es) | Composición farmacéutica que contiene irbesartán | |
EA024538B1 (ru) | Твердая фармацевтическая композиция, содержащая соединение с анти-вгс (hcv) активностью | |
CN1358090A (zh) | 左旋多巴/卡比多巴/恩他卡朋药物制剂 | |
US10105365B2 (en) | Solid antiviral dosage forms | |
CN1253497A (zh) | 含扑热息痛的吞咽片剂 | |
CN1805738A (zh) | 持续释放的二甲双胍片剂 | |
CN1705470A (zh) | 布洛芬钠的剂型 | |
CN1863517A (zh) | 快速崩解制剂 | |
CN1092963C (zh) | 解酸组合物和药物组合物 | |
CN1853631A (zh) | 含有帕罗西汀的快速崩解剂 | |
CN1183044A (zh) | 含有硫糖铝的制剂组合物 | |
CN1538837A (zh) | 含有对乙酰氨基酚的吞咽片 | |
CN1883480A (zh) | 一种含卢帕他定的药物组合物 | |
CN1552309A (zh) | 一种促进西洛他唑固体制剂药物溶出的方法 | |
CN104739835A (zh) | 一种治疗糖尿病的新型药物组合物 | |
CN1943561A (zh) | 普卢利沙星口腔崩解片及其制备方法 | |
CN1863512A (zh) | 控释药物组合物及其制备方法 | |
CN1188113C (zh) | 含有profen和其它活性化合物的组合的药物混合物 | |
CN1173698C (zh) | 包含包衣的雷尼替丁、碱式柠檬酸铋和硫糖铝的对胃肠障碍具有治疗作用的可口服给药的药物制剂 | |
CN1582927A (zh) | 一种尼莫地平口腔崩解片剂及其制备方法 | |
CN1695624A (zh) | 含有苦参素和甘草酸的药物组合物及其应用 | |
CN1698663A (zh) | 一种环形泡腾剂型及其制备方法 | |
CN1762341A (zh) | 治疗心脑血管疾病、肝脏疾病的丹参酚酸复合物及其应用 | |
CN1883507A (zh) | 一种感冒制剂泡腾片及其制备方法 | |
CN1857289A (zh) | 一种复方甘草酸及其盐的分散片剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: VENTURE PHARMACEUTICAL (HAINAN) CO., LTD. Free format text: FORMER OWNER: DEZHONG WANQUAN PHARMACEUTICALS TECH. DEV. CO., LTD., BEIJING Effective date: 20110321 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100089 WANQUAN BUILDING, NO. 3, JINZHUANG, SIJIQING, HAIDIAN DISTRICT, BEIJING TO: 570314 NO. 279, NANHAI AVENUE, HAIKOU CITY |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110321 Address after: 570314 No. 279 Nanhai Road, Haikou Patentee after: AVENTIS PHARMA (HAINAN) Co.,Ltd. Address before: 100089, Wanquan mansion, three Jin Zhuang, Haidian District, Beijing, Sijiqing Patentee before: Beijing D-Venturepharm Technology Development Co.,Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20090729 |
|
DD01 | Delivery of document by public notice |
Addressee: Wang Shifeng Document name: Notice of Termination of Patent Rights |
|
DD01 | Delivery of document by public notice |